

## TRANSFUSION MEDICINE DEPARTMENT PROCEDURE

#### CATEGORY: System-Level Clinical June 6, 2012 **ISSUE DATE: REVISION DATE:** January 2021 SUBJECT: **MASSIVE HEMORRHAGE PROTOCOL (MHP)** AND EMERGENCY RELEASED BLOOD AND BLOOD PRODUCTS

Page 1 of 11

Document Owner:	Name:
Charge Technologist	Marvin Jones
Update Schedule: Every three years, or sooner if required.	
Stakeholder Consultation and Review:	Date:
Intensivist Lead for MTP (Dr. Josee Theriault)	January 28, 2021
Transfusion Medicine Section Head (Dr. Lian	January 28, 2021
Widjanarko	
Transfusion Committee	January 28, 2021
Intensivist Lead for CCRT (Dr. Mary Catherine Kerr)	February 5, 2021
Nurse Clinician for CCRT (Renee Fillier)	November 27, 2020
Clinical Policies and Procedures Committee	March 3, 2021
Approval:	Date:
	March 3, 2021
Arsa Smith	
Lisa Smith, Executive Sponsor	
Clinical Policy and Procedure Committee	

### PURPOSE

The Transfusion Medicine Department (TMD or "blood bank") will issue emergency release blood/blood product coolers to any patient area upon request to facilitate optimal and timely patient care.

## PROCEDURE

### **MHP Indications**

MHP can be initiated by the most responsible physician in the following situations:

- Known substantial blood loss (estimated 1500 mL or greater than six (6) units packed red blood • cells) OR
- Uncontrolled hemorrhage and hemodynamic instability <u>OR</u>
- Ongoing bleeding after four (4) units of Group O packed red blood cells (PRBCs) OR
- For trauma patient: ABC score greater than or equal to two (2) OR
- Resuscitation intensity of greater or equal to four (4) units of fluid in the first thirty (30) minutes (fluid = one(1) unit PRBCs, one (1) unit plasma, 500mL colloid, or 1L or cystalloid)

**Obstetric MHP Criteria:** 

Blood loss of greater than 1000mL and uncontrolled bleeding •

### **Special Instructions**

- MHP is a Critical Care Response Team (CCRT) led protocol at HSN. The CCRT receive training and education specific to MHP.
- During a massive transfusion situation, various departments will work together to expedite the rapid response as per protocol described in this procedure.

- The TMD will issue either Group O Positive or O Negative packed red blood cells in coolers depending on patient age, sex and availability of blood product. Once pre-transfusion testing is complete, group-specific crossmatched red cell units and group-specific blood components will be issues in coolers during a MHP.
- During a MHP, the TMD will continue with subsequent steps in the preparation of blood and blood products. It is essential to notify the TMD immediately when deactivating the MHP.
- Up to a limit of two (2) emergency released uncrossmatched Group O packed red blood cells may be issued via pneumatic tube upon phone request from a responsible physician (or designate). Further need for uncrossmatched blood or blood products must be retrieved in coolers from the TMD (contact porter or use other transport personnel).
- Refer to the "Blood Product Administration" corporate clinical policy for requirements involving the safe administration of blood and blood products.
- Blood coolers are to be kept closed at all times until ready to transfuse.

## Method

See Appendix A for the MHP Algorithm See Appendix B for MHP Activation – Clinical Areas See Appendix C for MHP Activation – Switchboard See Appendix D for MHP Activation – Portering

## MHP - Completing the Transfusion Record

- 1. Prior to completion of pre-transfusion testing, products within the cooler will typically be tagged with <u>one</u> of the following:
  - Emergency Uncrossmatched Group O Issue Transfusion Record
  - Emergency Group AB Plasma Issue Transfusion Record
  - Emergency Platelet Issue Transfusion Record

# It is essential that <u>all</u> blanks on these forms are completed and contain the following information:

- Name (may be SRHUNIDENT, xxx, where xxx is a random generated first name)
- SH #
- ID check #1 and #2
- Transfusion start and end time with signatures
- 2. When the transfusion is complete and <u>all blanks are complete</u> on the above forms, place the "yellow" copy in the cooler for return to the TMD and place the "white" copy on the patient chart.
- 3. Once pre-transfusion testing is complete, the cooler for MHP will contain group-specific crossmatched red cells or group-specific blood components. These products will be tagged and accompanied with a "Blood Product Issue Transfusion Record" which should be completed and placed on the patient record after transfusion.
- 4. The first cooler issued will contain the "Doctor's Consent for the Release of Uncrossmatched Blood" form, which will require the signature of the requesting physician.
- 5. If red cell units in the cooler are not required, the cooler will be returned to the TMD by the ED cleaning and supply attendant, porters or other staff **as soon as possible** (no longer than 4 hours).
- 6. The TMD will contact the ED charge nurse (in the case of ED patients) or the requesting location (for MHP patients or other patients requiring emergency release coolers) to request a return of the cooler(s) as soon as crossmatched packed red cells are available.

## Emergency Release of Blood/Blood Product Coolers

- 1. In an emergency situation when there is not sufficient time to perform necessary pre-transfusion patient testing, the TMD will issue coolers with uncrossmatched or emergency released products. Products available for emergency release include:
  - Emergency uncrossmatched Group O packed red cells
  - Emergency released Group AB frozen plasma (thawed)
  - Emergency released platelets
- 2. Emergency release of blood and blood products in coolers can occur in the following situations:
  - Where the ED requires in anticipation of (or during) a trauma situation, the ED will activate the primary trauma team via numeric pager **# 0958** or by phoning the TMD at **ext. 3231 or 8615**. The TMD will automatically prepare two (2) units of Emergency Uncrossmatched Group O packed red cells in a cooler when notified by pager.
  - During a MHP
  - During other hemorrhagic events occurring in the hospital (i.e. Operating Room) by calling the TMD at ext. 3231 or 8615
- 3. Emergency released uncrossmatched packed red cells, platelets, Octaplex and Fibrinogen Concentrate should be ready within five (5) minutes of notification. Plasma (thawed) will typically be available within approximately 30 minutes of notification.
- 4. The requesting location will be responsible for dispatching personnel to retrieve the cooler from the TMD. **TMD staff will not transport coolers.**

## EDUCATION AND TRAINING

## **References and Related Documents**

Allard, C.B., Scarpelini, S. Rhind, S. G., Baker, A.J., Shet, P.N., Tien, H., Fernando, M., Tremblay, L., Morrison, L.J., Pinto, R. & Rizoli, S.B. (2009). Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. *The Journal of Trauma Injury, Infection and Critical Care.* 67:5. p. 959-967.

Barbosa, R.R., Rowell, S.E., Fox, E.E., Holcomb, J.B., Bulger, E.M., Phelan, H.A., Alarcon, L.H., Myers, J., Brasel, K.J., Muskat, P., del Junco, D.J., Cotton, B.A., Wade, C.E., Rahbar, M.H., Cohen, M.J. & Schreiber. (2013). Increasing time to operation is associated with decreased survival in patients with a positive FAST examination requiring emergent laparotomy. *Journal of Trauma and Acute Care Surgery*. 75:1. p. S48-52.

Beekley, A.C. (2008). Damage control resuscitation. Critical Care Medicine. 36:7, p.S267-S274.

Boffard, K.D., Riou, B., Warren, B., Iau Tsau Choong, P., Rizoli, S., Rossaint, R. Axelsen, M. & Klugger, Y. (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. *The Journal of Trauma Injury, Infection and Critical Care.* p. 8-18.

Borgman, M.A., Spinnela, P.C., Perkins, J.G., Grathwohl, K.W., Repine, T., Beekley, A.C., Sebesta, J., Jenkins, D., Wade, C.E. & Holcomb, J.B. (2007). The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. *The Journal of Trauma Injury, Infection and Critical Care.* 63:4. p. 805-813.

Bormanis, J. (2008). Development of a massive transfusion protocol. *Transfusion and Apheresis Science*. 38. p. 57-63.

Brohi, K., Cohen, M.J., Ganter, M.T., Schultz, M.J., Levi, M., Mackersie, R.C. & Pittet, J-F. (2008). Acute coagulapathy of trauma: Hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. *The Journal of Trauma Injury, Infection and Critical Care*. 64:5. p. 1211-1217.

Bruce, D. & Nokes T.J.C. (2008). Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. *Critical Care*. 12:4.

Callum, J., Yeh, C., McVey, M., Petrosoniak, A., Cope, S., Thompson, T., ... & Beno, S. (2019). A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus.

Campion, E.M., Pritts, T.A., Dorlac, W.C., Nguyen, A.Q., Fraley, S.M., Hanseman, D. & Robinson, B.R.H. (2013). Implementation of a military-derived damage-control rescuscitation strategy in a civilan trauma center decreases acute hypoxia in massively transfused patients. *Journal of Trauma and Acute Care Surgery*. 75:2. p. S221-227.

Canadian Blood Services. (2011). Prothrombin complex concentrate (PCC) comparison table.

Cardoso, T.A.A.M., Neto, C.N., dos Santos Silva, C.G., Lobo da Rocha, P & Losto, H.H.U. (2015). Use of lyophilized fibrinogen concentrate in cardiac surgery: a systematic review. *Heart, Lung and Vessels. Vol 7.* 

Cohen, M.J., Kitcher, M., Redick, B., Nelson, M., Call, M., Knudson, M., Schreiber, M.A., Bulger, E.M., Muskat, P., Alarcon, L.H., Myers, J., Rahbar, M.H., Brasel, K.J., Phelan, H.A., del Junco, D.J., Fox, E.E., Wade, C.E., Holcomb, J.B., Cotton, B.A. & Matijevic, N. (2013). Clinical and mechanistic drivers of acute traumatic coagulopathy. *Journal of Trauma and Acute Care Surgery*. 77:1. p. S40-47.

Cotton, B.A., Au, B.K., Nunez, T.C., Gunter, O.L., Robertson, A.M. & Young, P.P. (2009). Predefined massive transfusion protocols are associated with a reduction in organ failure and postinjury complications. *The Journal of Trauma Injury, Infection and Critical Care*. 66:1. p. 41-49.

Cotton, B.A., Dossett, L.A., Au, B.K., Nunez, T.C., Robertson, A.M. & Young, P.P. (2009). Room for (Performance) improvement: Provider-related factors associated with poor outcomes in massive transfusion. *The Journal of Trauma Injury, Infection and Critical Care*. 67:5. p. 1004-1012.

Cotton, B.A., Gunter, O.L., Isbell, J., Au, B.K., Robertson, A.M., Morris, J.A., St. Jacques, P. & Young, P.P. (2008). Damage control hematology: The impact of a trauma exsanguination protocol on survival and blood product utilization. *The Journal of Trauma Injury, Infection and Critical Care.* 64:5. p. 1177-1183.

Cotton, B.A., Podbielski, J., Camp, E., Welch, T., del Junco, D.J., bai, Y., Hobbs, R., Scroggins, J. Hartwell, B., Kozar, R.A., Wade, C.E. & Holcomb, J.B. (2013). A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. *Annals of Surgery*. 258:4. p.527-533.

del Junco, D.J., Holcomb, J.B., Fox, E.E., Brasel, K.J., Phelan, H.A., Bulger, E.M., Schreiber, M.A. Muskat, P., Alarcon, L.H., Cohen, M.J., Cotton, B.A., Wade, C.E., Myers, J.G. & Rahbar, M.H. (2013). Resuscitate early with plasma and platelets or balance blood products gradually: Findings from the PROMMITT study. *Journal of Trauma and Acute Care Surgery*. 74:7. p. S24-30.

Dente, C.J., Shaz, B.H., Nicholas, J.M., Harris, R.S., Wyrzykowski, A.D., Shah, A., Vercruysse, G.A., Feliciano, D.V., Rozycki, G.S., Salomone, J.P. & Ingram, W.L. (2009). Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion

protocol in a civilian level 1 trauma centre. *The Journal of Trauma Injury, Infection and Critical Care*. 66:6. p. 1616-1624.

Dickneite, G., Dorr, B., Kaspereit, F. & Tanaka, K. A. (2010). Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. The *Journal of Trauma Injury, Infection and Critical Care.* 68:5. p. 1151-1157.

Duchesne, J., Hunt, J.P., Wahl, G., Marr, A.B., Wang, Y-Z., Weintraub, S.E., Wright, M.J.O. & Mcswain, N.E. (2008). Review of current blood transfusion strategies in a mature level 1 trauma center: Were we wrong for the last 60 years? *The Journal of Trauma Injury, Infection and Critical Care*. 65:2. p.272-278.

Duchesne, J., Islam, T.M., Stuke, L., Timmer, J.R., Barbeau, J.M., Marr, A.B., Hunt, J.P. Dellavolpe, J.D., Wahl, G., Greiffenstein, P., Steeb, G.E., McGinness, C., Baker, C.C. & Mcswain, N.E.(2009). Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy. *The Journal of Trauma Injury, Infection and Critical Care*. 67:1. p.33-39.

Duchesne, J., Mathew, K.A., Marr, A.B., Pinsky, M.R., Barbeau, J.M. & Mcswain, N.E. (2008). Current evidence based guidelines for factor VIIa use in trauma: The good, the bad and the ugly. *The American Surgeon.* 74:12. p. 1159-1164.

Dzik, W.H., Blajchman, M.A., Fergusson, D., Hameed, M., Kirkpatrick, A., Korogyi, T., Logsetty, S., Keate, R., Stanworth, S., MacAdams, C. & Muirhead, B. (2011). Clinical review: Canadian national advisory committee on blood and blood products – Massive transfusion consensus conference 2011: report of the panel. *Critical Care.* 15:242.

Girdauskas, E., Kempfert, J., Kuntze, T., Borger, M.A., Enders, J., Fassl, J., Falk, V. & Mohr, F-W. (2010). Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: A prospective randomized trial. *The Journal of Thoracic and Cardiovascular Surgery.* 140:5. p.117-11.

Griffe, M.J., DeLoughery, T.G. & Thorborg, P.A. (2010). Coagulation management in massive bleeding. *Trauma and Transfusion.* p. 263-268.

Hampton, D.A., Fabricant, L.J., Differding, J., Diggs, B., Underwood, S., De La Cruz, D., Holcomb, J.B., Brasel, K.J., Cohen, M.J., Fox, E.E., Alarcon, L.H., Rahbar, M.H., Phelan, H.A., Bulger, E.M., Muskat, P., Myers, J.G., del Junco, D.J., Wade, C.E., Cotton, B.A. & Schreiber, M.A. (2013). Prehospital intravenous fluid is associated with increased survival in trauma patients. *Journal of Trauma and Acute Care Surgery*. p. S9-S15.

Hauser, C.J., Boffard, K., Dutton, R., Bernard, G.R., Croce, M.A., Holcomb, J.B., Leppaniemi, A., Parr, M., Vincent, J-L., Tortella, B.J., Dimisits, J. & Bouillon, B. (2010). Results of the CONTROL trial: Efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. *The Journal of Trauma Injury, Infection and Critical Care*. 69:3. p. 489-500.

Holcomb, J.B., Fox, E.E., Zhang, X., White, N., Wade, C.E., Cotton, B.A., del Junco, D.J., Bulger, E.M., Cohen, M.J., Schreiber, M.A., Myers, J.G., Brasel, K.J., Phelan, H.A., Alarcon, L.H., Muskat, P. & Rahbar, M.H. (2013). Cryoprecipitate use in the PROMMTT study. *Journal of Trauma and Acute Care Surgery.* 75:1. p. S31-S39.

Inaba, K., Branco, B.C., Rhee, P., Blackbourne, L.H., Holcomb, J.B., Teixeira, P.GR., Shulman, E., Nelson, J. & Demetriades, D. (2010). Impact of plasma transfusion in trauma patients who do not require massive transfusion. *Journal of the American College of Surgeons*. 210:6. p. 957-965.

Johansson, P.I. and Stensballe, J. (2010). Hemostatic resuscitation for massive bleeding: The paradigm of plasma and platelets – a review of the current literature. Transfusion. Vol 50. p. 701-710.

Ketchum, L., Hess, J.R. & Hiippala, S. (2011). Indications for early fresh frozen plasma, cryoprecipitate and platelet transfusion in trauma. *The Journal of Trauma Injury, Infection and Critical Care*. 60:6. p.S51-S58.

Kiraly, L.N., Underwood, S., Differding, J.A. & Schreiber, M.A. (2009). Transfusion of aged packed red blood cells results in decreased tissue oxygenation in critically injured trauma patients. *The Journal of Trauma Injury, Infection and Critical Care.* 67:1. p.29-32.

Liumbruno, G., Bennardello, F., Lattanzio, A., Piccoli, P., Rossetti, G. as Italian Society of Transfusion Medicine and Immunohematology (SIMTI) Working Party. (2009). Recommendations for the use of antithrombin concentrated and prothrombin complex concentrates. *Blood Transfusion*. Vol 7, p. 325-334.

Mell, M.W., O'Neil, A.S., Callcut, R.A., Acher, C.W., Hoch, J.R., Tefera, G & Turnipseed, W.D. (2010). Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm. Surgery. p. 955-962.

Meyer, M.A.S., Ostrowski, S.R., Windelov, N.A. & Johansson, P.I. (2011). Fibrinogen cencentrates for bleeding trauma patients: what is the evidence? Vox Sanguinous. International Society of Blood Transfusion.

Nunez, T.C., Dutton, W.D., May, A.K., Holcomb, J.B., Young, P.P & Cotton, B.A. (2010). Emergency department blood transfusion and early blood component requirement. *Transfusion.* Vol 50. p. 1914-1920.

Nunez, T.C., Voskresensky, I.V., Dossett, L.A., Shinall, R., Dutton, W.D. & Cotton, B.A. (2009). Early prediction of massive transfusion in trauma: Simple as ABC (Assessment of blood consumption)? *The Journal of Trauma Injury, Infection and Critical Care.* p. 346-352.

Nunez, T.C., Young, P.P., Holcomb, J.B. & Cotton, B.A. (2010). Creation, implementation, and maturation of a massive transfusion protocol for the exsanguinating trauma patient. *The Journal of Trauma Injury, Infection and Critical Care.* 68:6. p.1498-1505.

Rizoli, S.B., Nascimento, B., Osman, F., Netto, F.S., Kiss, A.. Callum, J., Brenneman, F.D., Tremblay, L. & Tien, H.C. (2006). Recombinant activated coagulation factor VII and bleeding trauma patients. *The Journal of Trauma Injury, Infection and Critical Care.* 61:6. p.1419-1425.

Schochl, H. Neinaber, U., Hofer, G., Voelchel, W., Jambor, C., Scharbert, G., Kosek-Langenecker, S. & Solomon, C. (2010). Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. *Critical Care.* 14:RS5.

Schochl, H. What does ROTEM add to the management of massive hemorrhage? Ludwig Boltzmann Institute for Experimental and Clinical Traumatology & AUVA Research Centre for Traumatology.

Shaz, B.H., Dente, C.J., Harris, R.S., MacLead, J.B. & Hillyer, C.D. (2009). Transfusion management of trauma patients. *Anesthesia and Analgesia.* 108:6. p. 1760-1768.

Shuja, F., Finkelstein, R.A., Fukudome, E., Duggan, M., Kheirbek, T., Hamwi, K., Fischer, T.H., Fikry, K., deMoya, M., Velmahos, G.C. & Alam, H.B. (2011). Development and testing of low-volume hypertomic, hyperosmotic spray-dried plasma for the treatment of trauma-associated coagulopathy. *The Journal of Trauma Injury, Infection and Critical Care.* Vol 70. p.664-671.

Snyder, C.W., Weingerg, J.A., McGwin, G., Melton, S.M., George, R.L., Reiff, D.A., Cross, J.M., Hubbard-Brown, J., Rue, L.W. & Kerby, J.D. (2009). The relationship of blood product ration to mortality: Survival benedfit or survival bias? *The Journal of Trauma Injury, Infection and Critical Care*. 66:2. p.358-364.

Sperry, J.L., Ochoa, J.B., Gunn, S.R., Alarcon, L.H., Minei, J.P., Cushieri, J., Rosengart, M.R., Maier, R.V., Billiar, T.R., Peitzman, A.B., Moore, E.E. and The Inflammation the Host Response to Injury Investigators. (2008). An FFP: PRBC transfusion ratio  $\geq$  1:1.5 is associated with a lower risk of mortality after massive transfusion. *The Journal of Trauma Injury, Infection and Critical Care.* 65:5. p.986-993.

Spinella, P.C. and Holcomb, J. (2009). Resuscitation and transfusion principles for traumatic hemorrhagic shock. *Blood Reviews*. Vol 23. p. 231-240.

Teixeira, P.G.R., Inaba, K., Shulman, I., Salim, A., Demetriades, D., Brown, C., Browder, T., Green, D. & Rhee, P. (2009). Impact of plasma transfusion in massively transfused trauma patients. *The Journal of Trauma Injury, Infection and Critical Care*. 66:3. p.693-697.

Theusinger, O.M., Spahn, D.R. & Ganter, M.T. (2009). Transfusion in trauma: Why and how should we change our current practice? *Trauma and Transfusion*. p.305-312.

vanRyn, J., Stangier, J., Haertter, S., Liesenfeld, K-H., Wienen, W., Feuring, M. & Clemens, A. (2010). Dabigatran etexilate- a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. *Thrombosis and Hemostasis.* p. 1116-1127.

Wafaisade, A., Wutzler, S., Lefering, R., Tjardes, T., Banerjee, M., Paffrath, T., Bouillon, B., Maegele, M. & Trauma Registry of DGU. (2010). Drivers of acute coagulopathy after severe trauma: A multivariate analysis of 1987 patients. *Emergency Medicine Journal*. p. 1-6.

Watson,G.A., Sperry, J.L., Rosengart, M.R., Minei, J.P., Hargrecht, B.G., Moore, E.E., Cuschieri, J., Maier, R.V., Billiar, T.R. & Peitzman, A.B and The Inflammation and the Host Response to Injury Investigators. (2009). Fresh frozen plasma is independently associated with a higher risk of multi-organ failure and acute respiratory distress syndrome. *The Journal of Trauma Injury, Infection and Critical Care.* 67:2. p.221-230.

Zarychansky, R. Supporting practice with evidence: Plasma & red cell ratios in massive transfusion. MTCC.



### APPENDIX B

## Activation of Massive Hemorrhage Protocol (MHP) – Clinical Areas

To ACTIVATE MHP, do the following:

- 1. Dial 5555 (Code Phone)
- 2. State:
  - a) Initiate Massive Hemorrhage Protocol as per Dr. \_
  - b) State patient's name
  - c) Provide patient's SH number
  - d) Location of MTP: i) Tower
    - ii) Level

## iii) Room Number

For Operating Room Staff Only: Call in perfusionist on call if required.

- Wait for Switchboard staff to repeat information for confirmation
- 4. If information is correct state, "Yes that is correct."

Document Control:

Document Owner: Marvin Jones, Charge Tech Transfusion Medicine Department

Program/Service Area: Laboratory Services, Transfusion Medicine

Date of Document May 11, 2016, Rev Jan 2021

Update Schedule : 2 years

#### APPENDIX C

## Activation of Massive Hemorrhage Protocol (MHP) – Switchboard

## The call for **MHP ACTIVATION** will come in on the CODE PHONE.

- A. You will hear "Initiate Massive Hemorrhage Protocol as per Dr. \_\_\_\_"
- B. Document:
  - 1. The patient's name
  - 2. SH number
  - 3. Location of the MHP
    - i. Tower
      - ii. Level
    - iii. Location of the MHP
- C. Repeat back the information. The caller will confirm information by stating, "Yes that is correct."
- D. Once confirmation received, you will immediately call overhead "Attention all staff. Code Transfusion \_\_\_\_\_ (location)" repeat 3 times.

#### E. FOLLOW WITH STAT CALLS TO:

- Transfusion Medicine Department at extension #3231 and repeat information given:
  - i. Massive Hemorrhage Protocol initiated by Dr. \_\_\_
  - ii. Provide patient name, SH number, location tower/level/room #
- 2. Porter Dispatch
  - i. Massive Hemorrhage Protocol initiated by Dr. \_\_\_
  - ii. Tower / level / room #
- 3. CCRT Nurse voice pager # 0888 Repeat information from step 2.
- 4. VCC Nurse voice pager #0137 Repeat information from step 2.
- 5. RRT voice pager #0146 Repeat information from step 2.
- 6. Intensivist on call Repeat information from step 2.
- \*For Operating Room MHP only\* the Operating Room will identify if perfusion-on call is required at MHP
- NOTE: If porter is delayed, advise CCRT by voice pager "Porter is delayed by xx minutes".

Document Owner: Marvin Jones, Charge Tech Transfusion Medicine Department
Program/Service Area: Laboratory Services, Transfusion Medicine
Date of Document: January 4, 2017, Rev Jan2021 Update Schedule : 2 years

#### APPENDIX D

# Activation of Massive Hemorrhage Protocol (MHP) – Porter

- 1. Respond immediately to location of MHP.
- Upon arrival, tell the team "My name is \_\_\_\_ I am the porter and need the patient's full name, date of birth, SH number to obtain blood products".
  - a. The team may give you lab samples to take down to the main Laboratory window (Level 1 Centre Tower room 1340)
  - b. Get blood products from Transfusion Medicine Department (Level 1 Center Tower). Wait outside of the window until products are ready. You will be given a dolly to transport blood products.
- 3. Once product delivered to patient location, return to the Transfusion Medicine window (Level 1 Center Tower Room 1333) with the dolly and wait for more blood product.
- 4. Repeat steps 2 and 3 until the MHP is terminated at which time you will be notified by the CCRT nurse. Coolers must be returned to Transfusion Medicine after the MHP is deactivated.

 Document Control:

 Document Owner: Marvin Jones, Charge Tech Transfusion Medicine Department

 Program/Service Area: Laboratory Services, Transfusion Medicine

 Date of Document June 14, 2016, Rev Jan 2021
 Update Schedule : 2 years